Fewer deaths reported with enrollment in COVID-19 remote monitoring
Nov 18, 2021
The remote monitoring service, COVID Watch, reduced deaths at 30 and 60 days and was associated with presentation to the emergency department sooner.
Delta variant accounts for most breakthrough SARS-CoV-2 cases
Aug 03, 2021
The delta variant was identified in 89% of patients with breakthrough infection; four of five hospitalized patients were vaccinated.
Effectiveness of Ad26.COV2.S vaccine stable for six months
Mar 22, 2022
A single dose of the Johnson & Johnson vaccine was 74% and 81% effective for preventing COVID-19 infection and hospitalizations, respectively, in the U.S. before and during delta variant surge.
Most immunosuppressive meds not tied to worse COVID-19 outcomes
Dec 01, 2021
Except for rituximab, no increased risk was seen for in-hospital death or mechanical ventilation for those on long-term immunosuppressive therapy.
Decline in infectious conjunctivitis during COVID-19 pandemic
Nov 29, 2021
There was a decrease in emergency department encounters for nonallergic conjunctivitis after the adoption of public health measures to curb COVID-19.
COVID-19 vaccine effectiveness changing with delta predominance
Sep 14, 2021
Vaccine protection against SARS-CoV-2 infection declined; protection remained higher against hospitalization, death.
COVID-19 vaccine booster dose cuts infection in those 60 and older
Sep 17, 2021
A large Israeli study shows a reduction in confirmed infection and severe illness among adults 60 years of age and older.
Fourth dose of BNT162b2 offers protection against severe COVID-19
Apr 08, 2022
Protection against COVID-19 did not wane in six weeks after receipt of fourth dose of the Pfizer–BioNTech vaccine; protection against the infection waned.
Survival high with ECMO for selected severe COVID-19 patients
Mar 10, 2022
Of 30 patients, 90% survived to discharge; survival was 86.7% at a median follow-up of 10.8 months since ECMO cannulation.
NVX-CoV2373 vaccine protects against COVID-19
Dec 27, 2021
A study conducted in the U.S. and Mexico shows that the vaccine is 90% effective overall and 100% effective against moderate-to-severe disease.